Ohio State Navbar

Research

Outpatient Trials


Pulmonary Arterial Hypertension Clinical Trials

Protocol Name: Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic patients with pulmonary arterial hypertension - A multicenter, double-blind, randomized, placebo-controlled, parallel group, prospective, event driven Phase IV study
Sponsor: Actelion
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this study is to evaluate how safe and how effective bosentan is in combination with sildenafil. The combination use will be compared to subjects receiving sildenafil only. Potential subjects will be patients using sildenafil for the treatment of pulmonary arterial hypertension (PAH) who still have symptoms.


Protocol Name: A 12-Week, International, Multicenter, Double Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT 15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension
Sponsor: United Therapeutics
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this research study is to determine if UT 15C SR will help control the symptoms of PAH and determine if it is safe.


Protocol Name: Long-term, single-arm, open label extension study of the SERAPHIN study, to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension
Sponsor: Actelion
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this research study is to test the safety, tolerability, and effectiveness of the investigational drug, ACT-064992, when used to treat pulmonary arterial hypertension.


Protocol Name: Randomized, double-blind, placebo-controlled, multicentre, multi national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). CHEST-1 Study
Sponsor: Bayer Healthcare AG
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug, BAY 63-2521, when used to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH).


Protocol Name: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH)- PATENT-1 Study
Sponsor: Bayer Healthcare AG
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug, BAY 63-2521, when used to treat pulmonary arterial hypertension (PAH).


Protocol Name: The expression and significance of miRNA profile and markers of inflammation in patients with pulmonary arterial hypertension
Sponsor: Pulmonary Division
PI: Namita Sood, MD
Coordinator: Megan Sustar
Synopsis: This study is being done to see if blood samples can be tested to determine who might develop PAH, how well drugs will work to treat PAH and to learn more about the development of PAH.


Protocol Name: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension
Sponsor: Gilead Sciences
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this study is to see if treatment with cicletanine for 12 weeks improves ability to exercise (exercise capacity) better than treatment with placebo for 12 weeks.


Protocol Name: ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
Sponsor: Gilead Sciences
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this study, which is also called the main study, is to evaluate the safety and effectiveness of ambrisentan compared to placebo (a tablet that looks like ambrisentan but contains no medicine) in subjects with PH associated with IPF.


Protocol Name: AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension
Sponsor: Gilead Sciences
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The purpose of this study is to test how well the study drugs ambrisentan and tadalafil work together to treat PAH compared to ambrisentan or tadalafil alone.


Protocol Name: A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension (GRIPHON)
Sponsor: Actelion
PI: Namita Sood, MD
Coordinator: Sharon Cheung
Synopsis: The main purpose of this clinical research study is to show that treatment with this new study drug (ACT-293987) delays the time to worsening of the disease.